Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.46 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622497 | 0.84 | CYP26A1 (0.70) | DGAT1ITGB3ITGA2BCYP26A1CYP24A1 | |
| SCHEMBL17195438 | 0.84 | CYP24A1 (0.46) | DGAT1ITGB3ITGA2BCYP26A1METAP1 | |
| SCHEMBL10341531 | 0.83 | CYP26A1 (0.59) | DGAT1ITGB3ITGA2BCYP26A1CYP19A1 | |
| SCHEMBL8534684 | 0.82 | DGAT1 (0.50) | DGAT1ITGB3ITGA2BCYP26A1PPARD | |
| SCHEMBL4621871 | 0.82 | CYP24A1 (0.68) | DGAT1ITGB3ITGA2BCYP26A1METAP1 | |
| SCHEMBL14060281 | 0.81 | DGAT1 (0.84) | DGAT1ITGB3ITGA2B | |
| SCHEMBL8531913 | 0.81 | CHRM2 (0.48) | DGAT1CYP26A1METAP1 | |
| SCHEMBL16503293 | 0.81 | PPARD (0.65) | PPARD | |
| SCHEMBL14567149 | 0.81 | PPARD (0.65) | PPARD | |
| SCHEMBL16503302 | 0.81 | PPARD (0.65) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624174-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-10 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9221766-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-5847159-A | 1- ω-(3,4-dihydro-2-naphthalenyl)alkyl!-cyclic amine derivatives, process for preparing the same, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| EP-0825180-A1 | 1-OMEGA-(3,4-DIHYDRO-2-NAPHTHALENYL)ALKYL] CYCLIC AMINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ITGB3 2673/4885ITGA2B 3109/4885 |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885ITGB3 3896/4885ITGA2B 3648/4885 |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ITGB3 2673/4885ITGA2B 3109/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | DGAT1 977/4885ITGB3 3109/4885ITGA2B 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.